The FDA’s Mood-Ring Era Meets Moderna's Flu Shot

In the age of “WMD” bills, the FDA chose plot over procedure

In Minnesota and Tennessee, lawmakers have decided that messenger RNA is not a molecule so much as a felony waiting to happen. In bill language that reads like it was drafted during a cable news segment and proofread by a guy who thinks Wikipedia is peer review, mRNA injections and products are described as “weapons of mass destruction.” Not metaphorically, not as a spicy rhetorical flourish, as in: “hello, state code, please hold my Red Bull.”

This is the atmosphere in which the federal government has been trying to conduct ordinary, boring, paperwork heavy regulation, which is the kind of activity you normally want the FDA doing. Quietly, predictably, with fewer plot twists than a prestige drama. Instead we got a week where the agency effectively told Moderna, “we are not even going to open the envelope,” and then promptly changed its mind.

Here is the update, in clean terms.

Moderna says the Food and Drug Administration has reversed its refusal to review the company’s mRNA flu vaccine and will now review it for possible approval, with a decision deadline in August. If it is authorized, Moderna says it could be available for older adults for the flu season that begins later this year. That is the plot, the vibes are the story.

Because the reversal is not just a bureaucratic correction, it is a public demonstration of how jittery, performative, and strangely personal vaccine policy has become. In the same week the vaccine industry was described as whispering about a chill, we watched a major regulator close a door, reopen it, and then explain the door was never really closed, it was carefully positioned in an evidence based manner, for transparency, and anyway please do not discuss it unless you have read the exact details. That line belongs to Marty Makary, the FDA commissioner, who addressed the earlier rejection at a PhRMA event and said, “you should know the exact details of the trial results.” He is right, the details matter, that is why we have regulators, so the rest of us do not have to cosplay as trial statisticians in our group chats.

What is hard to ignore is that none of this needed to be a spectacle. If the FDA thought Moderna’s filing had a problem, fine, say so, but why do it in a way that looks like a door slam followed by a stage whisper. Why not have the conversation the way grown up institutions usually do, with a memo, a checklist, and one of those polite sentences that translates to please fix this and come back. We are declining your application as submitted, if you make these adjustments, especially around the control vaccine in older adults, we can revisit. That is not weakness, that is literally what a process is.

Instead, we got refusal as performance, then reversal after “subsequent discussions,” which is a phrase that always makes you picture three people in suits discovering that maybe the internet will notice. Moderna, for its part, did what companies do when confronted with a regulator that suddenly feels like it is being run by a mood ring, it negotiated. The company says it split its application by age, seeking traditional approval for people 50 to 64, and accelerated approval for those 65 and older, plus a commitment to run an additional study in older adults after the vaccine reaches the market. Corporate aikido, the FDA gets to say it is insisting on stronger evidence in the highest risk population, Moderna gets to say it is still on track and being cooperative, and investors get to say, “okay, at least the lights are on again.”

If you have followed vaccine regulation for any amount of time, none of the underlying mechanics are shocking. The entire system runs on filings, meetings, endpoints, control arms, and a thousand small choices that determine whether a product gets reviewed promptly or ends up in procedural purgatory. Comparator disputes can be real science, older adults often use high dose or adjuvanted flu shots, and the best available option matters when you are evaluating a new product. The issue is not that regulators argue about comparators, the issue is that the argument became a public brawl that ended in a refusal, followed by a quick reversal after private talks. That sequence makes the process feel less like a stable system and more like a group chat, except the group chat can move markets.

And this is where the statehouse theatrics stop being just an internet punchline and start acting like accelerant. Because once legislators treat a biotech platform like a doomsday device, you are no longer living in a country where vaccine debates are simply what does the data say. You are living in a country where mRNA becomes a political object, a flag, a bumper sticker, a keyword, and a way of declaring your tribe. It is the kind of word you are not supposed to say at Thanksgiving if you want dessert.

That is why the New York Times published an almost aggressively normal article about what mRNA is and what it does, like a parent explaining, again, that water is wet and gravity is not a personal attack. The fact pattern is simple, mRNA was discovered in 1961, it exists in all our cells, and it carries information from DNA to the cell’s protein making machinery so proteins can be built. It is naturally programmed to degrade, which matters because the political storm depends on treating it like an invasive species that moves in, squats forever, and starts renaming the furniture.

A key move in the anti mRNA storyline is to suggest it lingers, alters you, rewrites you, and turns your genome into a corporate annex. The calm answer remains no, as noted in the Times article: “Our cells cannot convert the mRNA into DNA, which means it cannot be incorporated into our genome.” This is the part where the scientific method keeps winning even when the vibes are trying to take the trophy.

Does that mean mRNA vaccines are magic, risk free, and above criticism? No. Side effects like muscle aches and flu like symptoms are common and expected, immunity wanes over time and as viruses evolve, myocarditis concerns exist and should be monitored, and the credible way to talk about it is the way medicine always talks about anything, comparatively. A pediatric infectious disease specialist quoted by the Times said there are not long term safety signals after more than four years of Covid vaccine rollout, and pointed out that the risk of heart inflammation from Covid infection, as well as long Covid and other serious outcomes, is far greater. That is the difference between science and vibes. Science forces you to ask, “compared to what?” Vibes let you stop at “sounds scary.”

But vibes are running the show right now, and not just on TikTok. The Times notes that scientists with NIH funding were advised to scrub their grants of any reference to mRNA, and that state legislatures are considering bills to ban or limit such vaccines, including the aforementioned bill that describes them as “weapons of mass destruction.” And once you have that phrase floating in the air around a technology, it does not matter whether it is introduced as theater or passed as law. The introduction is the message: that a basic medical platform can be treated as contraband.

If you are a company thinking about building manufacturing capacity in a state, you cannot unread the phrase “weapons of mass destruction” sitting near the words possession and distribution. If you are a researcher writing a grant, you are not reassured by the idea that your work is safe as long as a committee does not decide your science is also a plot. If you are an investor, you do not say, “ah, it is only proposed,” you say, “interesting.” The regulatory tail risk has acquired a costume, and it is wearing a badge.

Hovering over all of this is Health Secretary Robert F. Kennedy Jr., who has repeatedly criticized mRNA as unsafe and ineffective, which is an opinion that lands differently when you are not a podcast guest but the person overseeing the institutions that touch vaccine policy. You do not need to invent a villain here; you just have to observe the contradiction. The federal government is insisting it is evidence based, while one of its most prominent voices has spent years teaching the public to suspect the platform. Institutions can say we are pro science until they are blue in the face, but markets and researchers read signals, everyone reads signals, because everyone must plan.

The cruel irony is that mRNA’s main practical advantage is speed and flexibility, and those are exactly the things you want in a world where viruses mutate like they are trying to win a prize. Flu strains are often chosen months before vaccines roll out, a faster manufacturing process means you can wait longer to see what is circulating and build a better match. This is not a partisan fantasy, it is logistics, it is the kind of boring advantage public health is built on.

Now place that next to the Moderna saga. Moderna’s mRNA flu vaccine is not just another product. It is a demonstration model for the platform’s promise beyond Covid, and Moderna has poured real money into it, including a $750 million investment from Blackstone. Then the FDA refused to accept the application for review, signed by Dr. Vinay Prasad, the agency’s top vaccine official, citing concerns about Moderna’s choice of control vaccine for older adults.

Again, comparator disputes can be real science, and older adults are not a rounding error. But a refusal to file is not a normal setback, it is the regulator telling you the work you did cannot even be evaluated because you did it wrong, after you already did it. That produces a very specific fear in every boardroom, not fear of scientific failure, but fear of bureaucratic invalidation.

Then the reversal happens, and you might think it should reassure everyone, and in some ways it does. Review is better than no review, a deadline is better than limbo, but the reversal also confirms the underlying complaint. The environment is unstable, and instability spreads. Moderna’s CEO, Stéphane Bancel, put it in earnings call language, “The current uncertainty in the U.S. F.D.A. regulatory environment creates real challenges for businesses, patients and the broader innovation ecosystem.” Translation: “this is a mess, and it is expensive.”

Here is what all of this suggests, taken together. The biggest issue for vaccine makers is not whether a particular product wins or loses, it is whether the pathway to approval is predictable enough to justify years of investment. The country can survive disagreement about endpoints and control arms, that is what science is for. It cannot thrive if the basic process starts to look like a performance, a public door slam followed by a walk back, in a political environment already primed to treat mRNA like contraband.

If the FDA review proceeds like a normal review and concludes with a clear decision based on public standards, this can become a footnote. If the whiplash continues, it becomes a pattern. And patterns are what markets, scientists, and viruses respond to. In the meantime, the molecule discovered in 1961 will keep doing what it does, quietly ferrying information so your cells can make proteins, indifferent to cable news, statehouse theatrics, and the fact that we have managed to turn the concept of a cellular memo into a culture war slogan, while the one institution that is supposed to be boring keeps grabbing the microphone.